- ►diabetesjournals.org T Nakamura, T Sugaya, Y Kawagoe, Y Ueda, … - Diabetes Care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Fifty-eight patients with type 2 diabetes (34 men
and 24 women, median age 52 years) and 20 healthy, age-matched subjects (group
E) were recruited for the study. The diabetic patients included 12 patients ... Cited by 23 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org K Suzuki, T Babazono, H Murata, Y Iwamoto - Diabetes care, 2005 - Am Diabetes Assoc Tubulointerstitial damage plays a crucial role in the progression of kidney
diseases, including diabetic nephropathy (1). Among several distinct types of
fatty acid–binding protein (FABP), liver-type FABP (l-FABP) is abundantly ... Cited by 9 - Related articles - BL Direct - All 5 versions
A Kamijo, K Kimura, T Sugaya, M Yamanouchi, … - The Journal of laboratory and clinical medicine, 2004 - Elsevier Previous studies have indicated that in massive proteinuria, free fatty acids
(FFAs) bound to albumin were overloaded in the proximal tubule and exacerbated
tubulointerstitial damage. Liver-type fatty acid–binding protein (L-FABP) ... Cited by 54 - Related articles - BL Direct - All 8 versions
T Nakamura, T Sugaya, Y Kawagoe, Y Ueda, … - Diabetes/Metabolism Reviews - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 13 - Related articles - BL Direct - All 3 versions
T Nakamura, T Sugaya, Y Kawagoe, Y Ueda, … - The American journal of the medical sciences, 2005 - journals.lww.com Background: Free fatty acids (FFAs) bound to albumin are overloaded in renal
proximal tubules and exacerbate tubulointerstitial damage. Liver-type fatty
acid-binding protein (L-FABP) is an intracellular carrier protein of FFAs ... Cited by 6 - Related articles - BL Direct - All 4 versions
- ►amjpathol.org A Kamijo-Ikemori, T Sugaya, A Obama, J Hiroi … - American Journal of Pathology, 2006 - ASIP The pathophysiological role of renal L-FABP in kidney disease has not yet been
fully clarified. Because renal L-FABP is not expressed in the kidneys of
rodents, we generated human L-FABP (hL-FABP) chromosomal transgenic (Tg) ... Cited by 12 - Related articles - BL Direct - All 7 versions
A Kamijo, T Sugaya, A Hikawa, M Yamanouchi, … - Molecular and cellular biochemistry, 2006 - Springer Page 1. Molecular and Cellular Biochemistry 284: 175–182, 2006. DOI:
10.1007/s11010-005-9047-9 c g Springer 2006 Urinary liver-type ... Cited by 29 - Related articles - BL Direct - All 4 versions
A Kamijo, T Sugaya, A Hikawa, M Yamanouchi, … - The Journal of laboratory and clinical medicine, 2005 - Elsevier To confirm the clinical usefulness of the measurement of urinary liver-type
fatty acid-binding protein (L-FABP) in chronic kidney disease (CKD), we carried
out a multicenter trial. Clinical markers were measured in patients with ... Cited by 30 - Related articles - All 6 versions
A Kamijo-Ikemori, T Sugaya, K Kimura - Clinica Chimica Acta, 2006 - Elsevier Liver type fatty acid binding protein (L-FABP) of 14.4 kDa is expressed in human
proximal tubules. In order to evaluate the clinical significance of urinary
L-FABP as a biomarker in renal disease, a monoclonal antibody against human ... Cited by 16 - Related articles - All 3 versions
T Nakamura, T Sugaya, K Node, Y Ueda, H … - American Journal of Kidney Diseases, 2006 - Elsevier Background: Administration of contrast agents can cause a decrease in renal
function and, occasionally, end-stage renal disease. Liver-type fatty
acid–binding protein (L-FABP) is an intracellular carrier protein of free ... Cited by 21 - Related articles - All 4 versions
